Biotechnological and Pharmacological Perspectives on Plant-Produced PD-L۱-Targeting Single-Domain Antibodies (VHHs/Nanobodies)

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 19

فایل این مقاله در 22 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_PBP-8-4_006

تاریخ نمایه سازی: 22 آبان 1405

چکیده مقاله:

Objective: Immune checkpoint inhibitors targeting the PD-۱/PD-L۱ axis have transformed cancer therapy, but conventional mAbs are limited by poor tumor penetration, prolonged systemic exposure, irAEs, and high production costs. VHHs and plant molecular farming may address these limitations, yet their integration remains largely unexplored. This scoping review summarizes evidence on PD-L۱ inhibition by VHHs, plant-based VHH production, ICI efficacy and safety in NSCLC, and VHH pharmacokinetics. Methods: Peer-reviewed studies published from ۲۰۱۲ to ۲۰۲۵ were identified through PubMed/MEDLINE, Web of Science, PDB, and ClinicalTrials.gov. Eligible studies addressed PD-L۱ structure, VHH engineering and production, plant-based expression, ICI outcomes in NSCLC, or nanobody pharmacokinetics. Data were systematically extracted, and methodological quality was assessed using RoB ۲, ROBINS-I, and AMSTAR ۲ according to study design. Results: From ۱,۲۴۷ records identified, ۱۴۹ full-text articles were assessed, and ۶۲ studies were included. Structural analysis identified key PD-L۱ hotspots (F۱۹, Y۵۶, R۱۱۳, M۱۱۵). The KN۰۳۵ nanobody (PDB: ۵JDS) competes with PD-۱ for the same surface on PD-L۱ through a ۲۱-amino-acid loop with approximately ۱,۰۰۰-fold stronger binding than PD-۱. VHHs (~۱۵ kDa) have short half-lives (hours) due to renal filtration. Plant expression of VHH-Fc fusions in Nicotiana benthamiana has been reported at yields up to ۱۱۰.۹۰ ± ۶.۴۶ mg/kg fresh weight, depending on subcellular targeting and protein engineering. No plant-produced anti-PD-L۱ VHH has been reported to date. Clinical data show that ICI combination regimens achieve HR OS as low as ۰.۵۶ (۹۵% CI ۰.۴۵–۰.۷۰) in the updated analysis of KEYNOTE-۱۸۹, with Grade ≥۳ immune-mediated adverse event rates of approximately ۸–۱۱% across ICI combination trials. No human clinical trial data exist for VHHs in NSCLC. Conclusions: Plant-produced VHHs represent a promising but currently unproven approach for PD-L۱ inhibition. The structural and pharmacological rationale is strong, but clinical and biotechnological evidence is lacking. Phase I/II trials and proof-of-concept plant expression studies are warranted.

نویسندگان

Maryam Behyari

Department of Cancer Cell and Molecular Biology, University of Leicester, Leicester, UK

Mahla Behyari

Department of Tissue Engineering, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Al-Showbaki L, et al. (۲۰۲۵). Anti-Programmed Cell Death-۱ Versus Anti-Programmed ...
  • Behyari M, Behyari M. Expression of Intragenic LCAL۴ Long Non-Coding ...
  • Behyari M. Investigation of LncRNA LCAL۴ as a new marker ...
  • Ge Y, et al. (۲۰۲۴). PD-(L)۱ inhibitors plus bevacizumab and ...
  • Giannetti M, et al. (۲۰۲۵). Unraveling the Specific Recognition Between ...
  • Hall G, et al. (۲۰۱۶). Structure-based design of a potent ...
  • Huyghe J, et al. (۲۰۱۸). Structural insights into PD-L۱ blockade ...
  • Muyldermans, S. (۲۰۱۳). Nanobodies: natural single-domain antibodies from camelids. Annu ...
  • Rhodes, S. J., & Adams, G. P. (۲۰۱۷). Immunoconjugates for ...
  • Sharpe, A. H., et al. (۲۰۱۵). The PD-۱/PD-L۱ pathway: an ...
  • Song C, et al. (۲۰۲۵). PD-۱/PD-L۱ inhibitors plus bevacizumab plus ...
  • Topalian, S. L., et al. (۲۰۱۲). Safety and activity of ...
  • Goto T, Nishida T, Takagi E, Miyao K, Koyama D, ...
  • Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, ...
  • Kang-Pettinger T, Walker K, Brown R, Cowan R, Wright H, ...
  • Córdova-Bahena L, Velasco-Velázquez MA. Anti-PD-۱ And Anti-PD-L۱ Antibodies as Immunotherapy ...
  • Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, ...
  • Shi D, Zhou S, Liu X, Zhao C, Liu H, ...
  • Liu H, Zhao Z, Zhang L, Li Y, Jain A, ...
  • Giannetti M, Gobbo M, Litti L, Caligiuri I, Rizzolio F, ...
  • Dong Y, Liu JJ, Zhou Y, Kang W, Li S, ...
  • Zheng Y, Wang Z, Weng Y, Sitosari H, He Y, ...
  • Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, ...
  • Meng H, Xu H, Wang X, Chen L, Yang F, ...
  • Liu H, Zhao Z, Zhang L, Li Y, Jain A, ...
  • Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, ...
  • Wu X, Meng Y, Liu L, Gong G, Zhang H, ...
  • Yang Y, Chen W, Dong L, Duan L, Gao P. ...
  • Al-Showbaki L, Al-Kasasbeh M, Jbarah K, Al-Nusair J, Yamin S, ...
  • Liu Z, Wang Z, Zhu J, Tao H, Huang Z, ...
  • Zhang J, Wu Z, Wang S, Sun Y, Wu J, ...
  • Ge Y, Zhan Y, He J, Li J, Wang J, ...
  • Song C, Qiu Y, Fan H, Han Y. PD-۱/PD-L۱ inhibitors ...
  • Li Y, Liang X, Li H, Chen X. Efficacy and ...
  • Yang Y, Chen W, Dong L, Duan L, Gao P. ...
  • Wenfan F, Manman X, Xingyuan S, Zeyong J, Jian Z, ...
  • Liu L, Yan Y, Wang Y, Li Z, Yang L, ...
  • Cong J, Wang A, Wang Y, Pi J, Liu K, ...
  • Liang J, Li M, Sui Q, Hu Z, Bian Y, ...
  • Ba H, Liu L, Peng Q, Chen J, Zhu YD. ...
  • Xie Z, Wang L, Yan Y, Hong R, Ou J, ...
  • Li ZQ, Yan HC, Gu JJ, Yang YL, Zhang MK, ...
  • Xiao J, Xia Z, Wu Z, Fang M. Clinical features, ...
  • Xiao J, Tang S, Xia Z, Zhou Y, Fang M. ...
  • Liu L, Yan Y, Wang Y, Li Z, Yang L, ...
  • Liang J, Li M, Sui Q, Hu Z, Bian Y, ...
  • Teng MM, Chen SY, Yang B, Wang Y, Han RY, ...
  • Wan N, Zhang TT, Hua SH, Lu ZL, Ji B, ...
  • Liao W, Huang J, Hutton D, Li Q. Cost-effectiveness analysis ...
  • Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, ...
  • She L, Hu H, Liao M, Xia X, Shi Y, ...
  • Nagai H, Takamaru N, Ohe G, Uchida D, Tamatani T, ...
  • نمایش کامل مراجع